加入收藏 | 设为首页 | 联系我们

产品搜索

相关文章

联系我们

联系人:蒋经理
电话:86-25-86880024
号码:86-25-86880024
手机:18066071954
地址:南京市雨花区长虹路222号
Email: duhaitao@cobioer.com

产品展示 / PRODUCTS
药靶细胞株 > kinase激酶细胞株 > CBP73198KIF5B(E15)-RET(E12) V804L/BaF3

KIF5B(E15)-RET(E12) V804L/BaF3
名称 KIF5B(E15)-RET(E12) V804L/BaF3
型号 CBP73198
报价
特点 KIF5B(E15)-RET(E12) [V804L]/BaF3,母细胞:BaF3,冻存条件:90% FBS+10% DMSO,培养基:RPMI-1640+10%FBS+1 ug/ml puromycin
  • 详细内容
" _ue_custom_node_="true">
CBP73198
I. Introduction

Cell Line Name:

KIF5B(E15)-RET(E12) [V804L]/BaF3

Gene Synonyms:

kinesin family member 5B ,HEL-S-61, KINH, KNS, KNS1, UKHC;ret proto-oncogene,CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC-ELE1, RET

Host Cell:

Ba/F3

Stability:16 passages

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS+1 ug/ml puromycin

Mycoplasma Status:

Negative

 
II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.

 
III. Representative Data

1. WB of KIF5B-RET [V804L]/BaF3

CBP73198 WB.png

 

2. Sanger of KIF5B-RET [V804L]/BaF3

CBP73198 sanger1.png

 

CBP73198 sanger2.png

 

3. Anti-proliferation assay

CBP73198 fig.jpg

Figure 4.CTG Proliferation Assay of BaF3 KIF5B-Ret (S) V804L Cells (C1).


如果你对CBP73198KIF5B(E15)-RET(E12) V804L/BaF3感兴趣,想了解更详细的产品信息,填写下表直接与厂家联系:


留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7
QQ在线客服
电话咨询
  • 25-86880024
  • 手机:18066071954

化工仪器网

推荐收藏该企业网站
扫一扫访问手机站扫一扫访问手机站
访问手机站